Serum soluble suppression of tumorigenicity 2 as a novel inflammatory marker predicts the severity of acute pancreatitis

Figure 1 Serum soluble suppression of tumorigenicity 2 level in acute pancreatitis patients and health control. AP: Acute pancreatitis; sST2: Soluble suppression of tumorigenicity 2.

Figure 2 Serum soluble suppression of tumorigenicity 2 level in acute pancreatitis patients. AP: Acute pancreatitis; MAP: Mild acute pancreatitis; MSAP: Moderately severe acute pancreatitis; SAP: Severe acute pancreatitis; sST2: Soluble suppression of tumorigenicity 2.

Figure 3 Serum C-reactive protein level in acute pancreatitis patients. AP: Acute pancreatitis; CRP: C-reactive protein; MAP: Mild acute pancreatitis; MSAP: Moderately severe acute pancreatitis; SAP: Severe acute pancreatitis.

Figure 4 Receiver operating characteristic curve demonstrating sensitivity as a function of 1 – specificity for predicting severe acute pancreatitis based on serum soluble suppression of tumorigenicity 2 levels. ROC: Receiver operating characteristic.